Standard BioTools Inc. (LAB)

Over the past six months, Standard BioTools' stock price has experienced fluctuations. As of January 5, 2026, the share price was $1.32, representing a decline of 25.42% from $1.77 on January 6, 2025. The 52-week range for the stock has been between $0.92 and $2.14. Key events impacting the stock include the merger with SomaLogic in January 2024, the preliminary Q4 and full year 2025 revenue announcement on January 8, 2026, a collaboration announcement with Molecular Instruments on November 19, 2025, the expected sale of SomaLogic to Illumina in the first half of 2026, and analyst ratings with a "Reduce" consensus rating for LAB shares.

Specific data on the demand seasonality for Standard BioTools, Inc.'s products and services is not explicitly detailed in the provided search results. Direct information regarding seasonal fluctuations in the sales or demand for their mass cytometry and microfluidics technologies, instruments, and consumables is not publicly available in the provided snippets.

Standard BioTools, Inc. (LAB) is a life sciences tools company focused on developing, manufacturing, and selling technologies for biomedical researchers. The company operates in the Healthcare sector, specifically in the Medical Devices industry, and is categorized under Life Sciences Tools and Services. Its core business provides insights into health and disease through mass cytometry and microfluidics technologies, serving applications in proteomics and genomics. The company's major products include preparatory and analytical instruments, consumables, and associated software and services. The Proteomics segment generates the majority of the company's revenue, serving a diverse global client base.

Standard BioTools, Inc. has a global presence, with a significant portion of its revenue derived from the Americas. The company's corporate headquarters are located in South San Francisco, California, USA. Other key locations and subsidiaries include offices in Boulder, Colorado, USA; Markham, Ontario, Canada; Paris, France; London, United Kingdom; Amstelveen, Netherlands; Munich, Germany; Milan, Italy; Shanghai, China; Singapore; and Tokyo, Japan.

Standard BioTools' brand reputation in the past year can be inferred from analyst sentiment and news related to its business activities. The consensus among Wall Street analysts is to "Reduce" LAB shares, with four "hold" ratings and one "sell" rating in the last year, and no "buy" or "strong buy" ratings. Positive events that could contribute to its reputation include the collaboration with Molecular Instruments, the launch of Illumina® Protein Prep, and the announcement of preliminary Q4 and full-year 2025 revenues.

Standard BioTools, Inc. has a significant level of institutional ownership. Major institutional owners include Casdin Capital, LLC, Viking Global Investors LP, BlackRock, Inc., Vanguard Group Inc, Mak Capital One Llc, Long Focus Capital Management, Llc, Morgan Stanley, Geode Capital Management, Llc and State Street Corp. Institutional investors collectively held over 313 million shares as of July 2025. As of November 2025, Casdin Capital LLC held approximately 20.168% of the company's ownership. Overall, 53.74% of the stock is held by institutions, and 23.16% by insiders.